Headquartered in Cologne (Germany), the international footprint of AYOXXA includes commercial and research operations in Singapore and commercial operations in Boston (USA).

We are a young and energetic company, guided by an experienced leadership, and determined to create research tools that boost translational research. Beyond facilitating discoveries in the lab, our LUNARIS™ Technology is the optimal analysis platform for the pre-clinical and clinical development work that transforms those discoveries into novel diagnostics and therapies.

From the start, the growth and development of AYOXXA has been in hands of visionary scientists and engaged entrepreneurs.

AYOXXA counts with the support of seasoned experts in finance, science and business to steer our company growth in a challenging, fast-paced market.

Institutional investors have made our work possible, but also private investors support our vision. These include a US investor, several of our employees, and some well-known and respected founders of important life sciences and biotechnology companies.

Investments are tax deductible, an incentive detailed in the INVEST program granted by BAFA of the German Federal Ministry for Economic Affairs and Energy.

AYOXXA operates within an extensive network of people and companies that have supported us from day one. We count on our collaborators in the biotech and life sciences industry for continuous exchange of insights, and validation of key strategic decisions before implementation.